Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients

Justin Ferdinandus; Pedro Fragoso Costa; Lukas Kessler; Manuel Weber; Nader Hirmas; Karina Kostbade; Sebastian Bauer; Martin Schuler; Marit Ahrens; Hans-Ulrich Schildhaus; Christoph Rischpler; Hong Grafe; Jens T. Siveke; Ken Herrmann; Wolfgang P. Fendler; Rainer Hamacher

doi:10.2967/jnumed.121.262468

Research ArticleClinical Investigation

Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients

Justin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler, Manuel Weber, Nader Hirmas, Karina Kostbade, Sebastian Bauer, Martin Schuler, Marit Ahrens, Hans-Ulrich Schildhaus, Christoph Rischpler, Hong Grafe, Jens T. Siveke, Ken Herrmann, Wolfgang P. Fendler and Rainer Hamacher

Journal of Nuclear Medicine May 2022, 63 (5) 727-734; DOI: https://doi.org/10.2967/jnumed.121.262468

Justin Ferdinandus

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Pedro Fragoso Costa

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lukas Kessler

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Manuel Weber

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nader Hirmas

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Karina Kostbade

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sebastian Bauer

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martin Schuler

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marit Ahrens

4Medical Clinic II, University Hospital Frankfurt, Frankfurt am Main, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hans-Ulrich Schildhaus

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

5Department of Pathology, West German Cancer Center, University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christoph Rischpler

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hong Grafe

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jens T. Siveke

3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;

6Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Medicine Essen, Essen, Germany; and

7Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, Partner Site Essen) and German Cancer Research Center (DKFZ), Heidelberg, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ken Herrmann

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wolfgang P. Fendler

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Rainer Hamacher

2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;

3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 63, Issue 5

May 1, 2022

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients

Journal of Nuclear Medicine May 2022, 63 (5) 727-734; DOI: 10.2967/jnumed.121.262468

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients

Journal of Nuclear Medicine May 2022, 63 (5) 727-734; DOI: 10.2967/jnumed.121.262468

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

FAPI
theranostics
fibroblast activation protein
solid tumors

Main menu

User menu

Search

Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords